Compare UAC & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UAC | CNTB |
|---|---|---|
| Founded | 2025 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 137.6M | 135.7M |
| IPO Year | 2025 | 2020 |
| Metric | UAC | CNTB |
|---|---|---|
| Price | $9.96 | $2.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.67 |
| AVG Volume (30 Days) | 1.6K | ★ 345.5K |
| Earning Date | N/A | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $64,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.51 | $1.23 |
| 52 Week High | $9.99 | $3.82 |
| Indicator | UAC | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 56.05 | 51.02 |
| Support Level | $9.92 | $2.30 |
| Resistance Level | $9.97 | $2.69 |
| Average True Range (ATR) | 0.01 | 0.16 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 66.67 | 45.00 |
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.